Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure

Medical Science Monitor

Volumn 9, Issue 7, 2003, Pages

  Hayden, Melvin R ^a,c   Tyagi, Suresh C ^b  

^a University of Missouri   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Dept of Fam and Community Medicine ^*  (United States)

Author keywords

Antioxidant; Antiredoxidant; Atheroscleropathy; Atherosclerosis; Free radicals; Nitric oxide (eNO); Nitric oxide synthase (eNOS) or (NOS 3); Oxidative stress; Reactive oxygen dpecies (ROS)

Indexed keywords

ANTIOXIDANT; GELATINASE INHIBITOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CARDIOMYOPATHY; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; DIASTOLE; ENDOTHELIUM CELL; EXERCISE; EXTRACELLULAR MATRIX; HEART DISEASE; HEART MUSCLE METABOLISM; HEART VENTRICLE REMODELING; HUMAN; INSULIN RESISTANCE; INTIMA; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVERNUTRITION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; SYSTOLE;

CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; EXTRACELLULAR MATRIX; HEART FAILURE, CONGESTIVE; HUMANS; INSULIN RESISTANCE; MATRIX METALLOPROTEINASE 9; METABOLIC SYNDROME X; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OBESITY; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 0042971701     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (112)

1. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA, 1979; 241(19): 2035-2038
2. Vasan RS, Levy D: The role of hypertension in the pathogenesis of heart failure: A clinical mechanistic overview. Arch Intern Med, 1996; 156: 1789-1796
3. Levy D, Larson MG, Vasan RS et al: The progression from hypertension to congestive heart failure. JAMA, 1996; 275(20): 1604-1606
4. Remme WJ: Overview of the relationship between ischemia and congestive heart failure. Clin. Cardiol, 2000; 23(7)(Sup IV): IV-4-IV-8
5. Levy D, Larson MG, Vasan RS et al: The progression from hypertension to congestive heart failure. JAMA, 1996; 275(20): 1557-1562
6. Hunt SA, Baker DW, Chin MH et al: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant, 2002; 21(2): 189-203
7. American Heart Association: 1999 Heart and Stroke Statistical Update. American Heart Association. Dallas, Texas. 1998.
8. Gomberg-Maitland M, Baran DA, Fuster V: Treatment of Congestive Heart Failure. Guidelines for the primary care physician and the heart failure specialist. Arch Intern Med, 2001; 161: 342-352.
9. Gu K, Cowic CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA, 1999; 281(14): 1291-1297
10. Redfield MM, Jacobsen SJ, Burnett JC Jr et al: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289(2): 194-202
11. Redfield MM: Heart failure - an epidemic of uncertain proportions. N Engl J Med, 2002; 347(18): 1442-1444
12. McCullough PA, Philbin EF, Spertus JA et al: Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol, 2002; 39(1): 60-69
13. Miller LW, Missov ED: Epidemiology of heart failure. Cardiol Clin, 2001; 19(4): 547-555
14. Cleland JG, Khand A, Clark A: The heart failure epidemic: exactly how big is it? Eur Heart J, 2001; 22(8): 623-6
15. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 1988; 37(12): 1595-1607
16. lozzo P, Chareonthaitawee P, Dutka D et al: Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes, 2002; 51 (10): 3020-3024
17. Youssef AA, Valdez R, Elkasabany A et al: Time course of adiposity and fasting insulin from childhood to young adulthood in offspring or parents with coronary - artery disease: the Bogalusa Heart Study. Ann Epidemiol, 2002; 12(8): 553-559
18. Erkelens DW: Insulin resistance syndrome and type 2 diabetes mellitus. Am J Cardiol, 2001; 88(7B): 38J-42J
19. Shen WH, Jeng CY, Young MS et al: Coronary artery disease risk predicted by insulin resistance, plasma lipids, and hypertension in people without diabetes. Am J Med Sci, 2000; 319(2): 84-88
20. Tuttle KR, Puhlman ME, Cooney SK, Short R: Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study. Am J Kidney Dis, 1999; 34(5): 918-925
21. Psyrogiannis AJ, Alexopoulos DK, Kyriazopoulou VE, Vagenakis AG: Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in patients with coronary artery disease independent of obesity. Angiology, 1998; 49(8): 607-612.
22. Tsuchihashi K, Hikita N, Hase M et al: Role of hyperinsulinemia in atherosclerotic coronary: arterial disease: studies of semiquantitative coronary angiography. Intern Med, 1999; 38(9): 691-697
23. Haffner SM: Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol, 1999; 84(1A): 11J-14J
24. Sobel BF.: The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes. Proc Assoc Am Physicians, 1999; 111(4): 313-318
25. Baillie GM, Sherer JT, Weart CW: Insulin and coronary artery disease: is syndrome X the unifying hypothesis? Ann Pharmacother, 1998; 32(2): 233-247
26. Miyawaki R, Urabe Y, Furuki T et al: Hyperinsulinemia in patients with spastic angina pectoris. Cardiology, 1997; 503-508
27. Ariza CR, Frati AC, Gomez G, Almazan A: Hyperinsulinemia in patients with coronary heart disease in absence of overt risk factors. Arch Med Res, 1997; 28(1): 115-119
28. Tomono S, Kato N, Utsugi T et al: The role of insulin in coronary atherosclerosis. Diabetes Res Clin Pract, 1994; 22(2-3): 117-122
29. Reaven G: Metabolic Syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation, 2002; 106: 286-288
30. Grundy SM: United States Cholesterol Guidelines, 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. Am J Cardiol, 2001; 88(7B): 23J-27J
31. Alberti KGM, Zimmet PZ: For the WHO Consultation: Delinition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med, 1998; 15: 539-553
32. Hayden MR, Tyagi SC: 'A' is for amylin and amyloid in type 2 diabetes mellitus. JOP. J Pancreas (Online), 2001; 2(4): 124-139. www.joplink.net
33. Hayden MR, Tyagi SC: Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome, and amylin derived islet amyloid in type 2 diabetes mellitus. JOP. J Pancreas (Online), 2002; 3(4): 86-108. www.joplink.net
34. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA, 2002; 287(3): 356-359
35. Jones LC, Clark A: Beta cell neogenesis in type 2 diabetes mellitus. Diabetes, 2001; 50(Suppl 1): S186-S187
36. Guiot Y, Sempoux C, Moulin P et al: No decrease of the beta cell mass in type 2 patients. Diabetes, 2001; 50(Suppl 1): S188
37. Bonora E, Kiechl S, Willeit J et al: Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: Prospective data from the Bruneck Study. Diabetes Care 26: 1251-1257
38. Hayden MR, Tyagi SC: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? Cardiovascular Diabetology, 2003; 2: 2 http://www.cardiab.com
39. Hayden MR, Tyagi SC: Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy Cardiovascular Diabetology, 2002; 1: 3 http://www.cardiab.com
40. O'Rahilly S: Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ, 1997; 314(7085): 955-959
41. Grundy SM: Metabolic complications of obesity. Endocrine, 2000; 13(2): 155-165
42. Kenchaiah S, Evans JC, Levy D et al: Obesity and the risk of heart failure. N Engl J Med, 2002; 347(5): 305-313
43. Husakove J, Jasenkova E, Murin J et al: The incidence and the characteristics of heart failure patients at a large medical department. Bratisl Lek Listy, 2002; 103(10): 385-389
44. Schunkert H: Obesity and target organ damage: the heart. Int J Obes Relat Metab Disord, 2002; 26 Suppl 4: 815-820
45. Goran MI, Ball GD, Cruz ML: Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab 2003; 88: 1417-1427
46. Oberley LW: Free radical and diabetes. Free Radic Bio Med, 1988; 5: 113-124
47. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H Oxidase Role in cardiovascular biology and disease. Circulation Research, 2000; 86(5): 494-501
48. Babior BM: NADPH oxidase: an update. Blood, 1999; 93(5): 1464-1476
49. McCord JM, Fridovich I: Superoxide dismutase: the first twenty years (1968-1988). Free Radic Biol Med, 1988; 5(5-6): 363-369
50. Roos D, Weening RS, Wyss SR et al: Protection of human neutrophils by endogenous catalase: Studies with cells from catalase-deficient individuals. J Clin Invest, 1980; 65(6): 1515-1522
51. Lawrence RA, Burk RF. Species, tissue and subcellular distribution of selenium dependent, glutathione peroxidase activity. J Nutr, 1978; 108(6): 981-987
52. Tyagi SC Ratajska A, Weber KT. Myocardial matrix metalloproteinases: Localization and activation. Mol Cell Biochem, 1993; 126: 49-59
53. Rajagopalan S, Meng XP, Ramasamy S et al: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest, 1996; 98: 2572-2579
54. Lefer DJ, Granger DN: Oxidative stress and cardiac disease. Am J Med, 2000; 109(4): 315-23
55. Hunt MJ, Aru GM, Hayden MR et al: Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol, 2002; 283(2): L239-L245
56. Dhalla NS, Elmoselhi AB, Hata T et al: Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res, 2000; 47(3): 446-456
57. Sigusch HH, Campbell SE, Weber KT: Angiotensin II-induced myocardial fibrosis in rats: Role of nitric oxide, prostaglandins and bradykinin. Cardiovasc Res, 1996; 31: 546-554
58. Booz GW, Baker KM: Molecular signaling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res, 1995; 30: 537-543
59. Kolpakov V, Gordon D, Kulik TJ: Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cell. Circ Res, 1995; 76: 305-309
60. Hingtgen SD, Davisson RL: Gene therapeutic approaches to oxidative stress-induced cardiac disease: principles, progress, and prospects. Antiox Redox Signal, 2001; 3(3): 433-449
61. Tyagi SC: Homocyst(c)ine and heart disease: Pathophysiology of extracellular matrix. Clin and Exper Hypertension, 1999; 21(3): 181-198
62. Mujumdar VS, Hayden MR, Tyagi SC: Homocyst(e)inc induces calcium second messenger in vascular smooth muscle cells. Journal of Cellular Physiology, 2000; 183: 28-36
63. Glasser SI: Hypertension syndrome and cardiovascular events: High blood pressure is only one risk factor. Postgraduate Medicine, 2001; 110(5): 29-36
64. Mosterd A, Hoes AW, deBroyne MC et al: Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J, 1999; 20: 47-455
65. Kupari M, Lindroos M, Iivanainen AM et al: Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med, 1997; 241: 387-394
66. Senni M, Tribouilloy CM, Rodeheffer RJ et al: Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation, 1998; 98: 2282-2289
67. Vasan RS, Levy D: Defining diastolic heart failure: A call for standardized diagnostic criteria. Circulation, 2000; 101(17): 2118-2126
68. Chatham JC, Forder JR, McNeill JH: The Heart in Diabetes 1996. Kluwer Academic Publishers, 101 Phillip Drive, Assinippi Park, Norwell, Massachusetts 02061
69. Kannel WB, Hjortland, Castelli WP: Role of diabetes in congestive heart failure: The Faramingham Study. Am J Cardiol, 1974; 34: 29
70. Sowers JR, Epstein M: Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. Hypertension, 1995; 26: 869-879
71. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension, 2001; 37(4): 1053-1059
72. Zabalgoitia M, Ismaeil MF, Anderson L et al: Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol, 2001; 87(3): 320-323
73. Meredith JE Jr, Fazeli B, Schwartz MA: The extracellular matrix as a cell survival factor. Mol Biol Cell, 1993; 4(9): 953-961
74. Rossi MA, Abreu MA, Santoro LB: Connective tissue skeleton of the human heart. A demonstration by cell-maceration scanning electron microscope method. Circulation, 1998; 97: 934-935
75. Weber KT: Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation. Circulation, 1997; 96: 4065-4082
76. Weber KT, Pick R, Janicki JS et al: Inadequate collagen tethers in dilated cardiopathy. Am Heart J, 1988; 116(6 Pt 1): 1641-1646
77. Weber KT: Extracellular matrix remodeling in heart failure: A role for De Novo angiotensin II generation. Circulation, 1997; 96: 4O65-4O82
78. Uemura S, Matsushita H, Li W et al: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res, 2001; 88: 1291-1298
79. Bauters C, Lamblin N, Mc Fadden EP et al: Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol, 2003; 2(1)1: http://www.cardiab.com
80. Zucker JS: Cardiac Dilatation. Gustav Fischer Verlag. Stuttgart. New York, 1990
81. Li H, Simon H, Bocan TM et al: MMP/TIMP expression in spontaneously hypertensive heart failure rats: The effect of ΛCE-and MMP-inhibition. Cardiovasc Res, 2000; 46(2): 298-306
82. Naglich JG, Jure-Kunkel M, Gupta E et al: Inhibition of angiogenesis and Metastasis in two murine models by the matrix metalloproteinases inhibitor, BMS-275291. Cancer Res 2001; 61(23): 8480-8485
83. Chowdury MH, Moak SA, Rifkin BR et al: Effect of tetracyclines which have metalloproteinase inhibitory capacity on basal and heparin-stimulatcd bone resorption by chick osteoclasts. Agents & Actions, 1993; 40(1-2): 124-8, 1993
84. Breedveldt FC, Dijkmans BAC, Mattie H: Minocycline treatment for rheumatoid arthritis: an open dose finding study. J. Rheumatol, 1990; 17: 43-46
85. Rubler S, Dlugash J, Yuceoglu YZ et al: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol, 1972; 30: 595-602
86. Kannel WB, Hjortland M, Castelli WP: Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol, 1974; 34(1): 29-34
87. Regan TJ, Lyons MM, Ahmed SS et al: Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest, 1977; 60: 885-899
88. Blumenthal HT, Alex M, Goldenberg S: A study of lesions of the intramural coronary branches in diabetes mellitus. Arch. Pathol, 1960; 70: 27-42
89. Ledet T: Histological and histochemical changes in the coronary arteries of old diabetic patients. Diabetologia, 1968; 4: 268-272
90. Ledet T: Diabetic cardiomyopathy: Quantitative histological studies of the heart from young juvenile diabetics. Acta Pathol. Microbiol Scand. (A), 1976; 421-428
91. Zoneraich S, Silverman G: Myocardial small vessel disease in diabetic patients. In: Zoneraich S, ed. Diabetes and the Heart. Springfield, IL: Charles C. Thomas, 1978; 3-18
92. Crall FV, Roberts WC: The extramural and intramural coronary arteries in juvenile diabetes mellitus: analysis of nine necropsy patients aged 19 to 38 years with onset of diabetes before age 15 years. Am. J. Med, 1978; 64: 221-230
93. Sunni S, Bishop SP, Kent SP et al: Diabetic cardiomyopathy. A morphological study of intramyocardial arteries. Arch Pathol Lab Med, 1986; 110: 375-381
94. Tasca C, Stefancanu I., Vasilescu C: The myocardial microangiopathy in human and experimental diabetes mellitus. (A microscopic, ultrastructural, morphometric and computer-assisted symbolic-logic analysis). Endrocrinologie, 1986; 24: 59-69
95. Silver MD, Huckell VS, Lorber M: Basement membranes of small cardiac vessels in patients with diabetes and myxedema: Preliminary observations. Pathology, 1977; 9: 213-220
96. Fischer VW, Barner HB, Leskiw L: Capillary basal laminar thickness in diabetic human myocardium. Diabetes, 1979; 28: 713-719
97. Factor SM, Okum EM, Minase T: Capillary microaneurysm in the human diabetic heart. N Engl J Med, 1980; 302: 384-388
98. Factor SM, Minase T, Sonnenblick EH: Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am Heart J, 1980; 790: 446-459
99. Nitenberg A, Paycha F, Ledoux S et al: Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin dependent diabetic patients with anglographically normal coronary arteries and no other risk factors. Circulation, 1998; 97: 736-743
100. Nahser Jr PJ, Brown RE, Oskarsson H et al: Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation, 1995; 91: 635-640
101. Sampaio RC, Planus-Santos JE, Melo SE et al: Hypertension plus diabetes mimics the cardiomyopathy induced by nitric oxide inhibition in rats. Chest, 2002; 122(4): 1412-1420
102. Abaci A, Oguzhan A, Kahraman S et al: Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation, 1999; 99(17): 2239-2242
103. Tyagi SC, Hayden MR: Role of nitric oxide in matrix remodeling in diabetes and heart failure. Molecular and genetic causes of endothelial dysfunction. Heart Failure Reviews, 2003; 8(1): 23-28
104. Duplain H, Burcelin R, Saltori C et al: Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation, 2001; 104: 342-345
105. Dagogo-Jack S: Preventing diabetes-related morbidity and mortality in the primary care setting. J Natl Med Assoc, 2002; 94(7): 549-560
106. Moneva MH, Dagogo-Jack S: Multiple drug targets in the management of type 2 diabetes. Curr Drug Targets, 2002; 3(3): 203-221
107. Gaede P, Vedel P, Larsen N et al: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003; 348: 383-393
108. Solomon CG: Reducing cardiovascular risk in type 2 diabetes. N Engl J Med, 2003; 348: 457-459
109. Benz D, Cadet P, Mantione K et al: Tonal nitric oxide and health - a free radical and a scavenger of free radicals. Med Sci Monit, 2002; 8(1): RA1-RA4
110. Korantzopoulos P, Galaris D, Papaioannides D et al: The possible role of oxidative stress in heart failure and the potential of antioxidant intervention. Med Sci Monit, 2003; 9(6): RA119-RA124
111. Heymes C, Bendall JK, Ratajczak P et al: Increased myocardial NADPH oxidase activity ill human heart failure. J Am Coll Cardiol, 2003; 11(12): 2164-2171
112. Ceriello A: New insights on oxidative stress and diabetic complications may lead to a 'causal' antioxidant therapy. Diabetes Care, 2003 26(5): 1589-1596